Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Latest adenosine Stories

2008-11-11 09:00:47

HemoBioTech, Inc. (OTCBB: HMB) (www.hemobiotech.com) announced today that Dr. Arthur P. Bollon, its Chairman & CEO, will make a company presentation at the Rodman & Renshaw 10th Annual Healthcare Conference on November 12, at 12 noon. The meeting will be held at The New York Palace Hotel in New York City. The conference is a leading health care conference involving venture capital and investment banking firms and analysts specializing in health care. Dr. Bollon will review the...

2008-09-17 21:00:20

By Lydia Gehring During a change of routine many people change their intake of caffeinated beverages. They may miss their morning coffee or perhaps increase their intake of caffeinated soda pops. Getting a headache or becoming irritable in the morning after missing a morning cup of tea or coffee could signal a caffeine addiction reaction. This is a fact because I just spent four days away from home and had a headache on Day No. 3. I sought out a cup of hot tea and after leaving the tea...

2008-08-12 09:01:36

LA JOLLA, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (BULLETIN BOARD: DSKA) ("Duska") announced today that it has received comments from the U.S. Food and Drug Administration's (the "FDA") Division of Cardiovascular and Renal Products on a synopsis of a proposed Phase 3 clinical study with its lead drug, ATPace(TM), for the acute treatment of a frequent cardiac arrhythmia called paroxysmal supraventricular tachycardia (PSVT). On April 16, 2008, Duska met with the...

2008-08-05 06:00:46

Clinical Data, Inc. (NASDAQ:CLDA) today announced the acquisition of Adenosine Therapeutics, L.L.C., a developer of drug products based on its extensive portfolio of composition of matter and method of use patents relating to selective adenosine receptor modulators. In exchange for all of the company's operating assets, Clinical Data paid $11 million in cash, and entered into a $22 million, five-year promissory note and a separate $3.2 million, 32-month promissory note. Contingent...

2008-07-25 09:00:33

SCHAUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched amiodarone HCl injection, USP, a class III antiarrhythmic indicated for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia -- a potentially life-threatening irregular heart beat. Sagent's amiodarone HCl injection will be available immediately in 150 mg/3...

2008-07-23 09:01:21

LA JOLLA, Calif., July 23 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (BULLETIN BOARD: DSKA) ("Duska") announced today that it has submitted for comment a synopsis of a proposed Phase 3 clinical study for its lead drug, ATPace(TM), to the U.S. Food and Drug Administration's (the "FDA") Division of Cardiovascular and Renal Products. Based on recent communications with the FDA, including a face-to-face meeting held on April 16, 2008, Duska believes that the proposed single,...

2008-06-24 09:01:41

DEERFIELD, Ill., June 24 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the commercial availability of Lexiscan(TM) (regadenoson) injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide MPI -- a test that detects and characterizes coronary artery disease -- in patients unable to undergo adequate exercise stress. Lexiscan, co-developed with CV Therapeutics , is the first A2A adenosine receptor agonist shown to be safe and effective as a...

2008-06-18 15:00:45

Inotek Pharmaceuticals Corporation announced today that it has begun enrollment in a Phase 1 clinical trial with the Company's selective Adenosine 1 agonist, INO-8875, for the treatment of glaucoma. In March, Inotek received approval from the U.S. Food and Drug Administration to advance INO-8875 into clinical trials. The initial study will evaluate the safety, tolerability, and the potential of INO-8875 to lower intraocular pressure (IOP) in glaucoma patients. Glaucoma patients typically have...

7a7113e76d752ce702ef453f02b1d85b1
2006-09-07 12:30:00

People who must stay awake for long shifts "“ soldiers, pilots, truckers, students, doctors, parents of newborns "“ may take comfort from new research showing that preventing the gas nitric oxide from building up in the brain may ward off the sleep urge. The research, conducted by investigators from Children's Hospital Boston and the University of Helsinki (Helsinki, Finland), ties together previous observations about sleep and finds that nitric oxide production in a specific...

8c352eb4a433a49856d6644dbcb55ebb1
2005-10-13 13:50:00

Discovery could explain why some experience deeper slumber than others Swiss researchers have identified a gene variation that might explain why some of us are sound sleepers, and some are not. "Animal studies suggested that sleep intensity is under genetic control, yet the physiological mechanisms remain unknown," explained study author Hans-Peter Landolt, an associate professor at the University of Zurich. His report appears in this week's issue of the Proceedings of the National Academy of...